Citigroup’s Allarity Therapeutics ALLR Stock Holding History

Citigroup’s Portfolio ALLR Stock Details ALLR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,766	Closed	-$8.46K	–	5701
2026 Q1	$8.46K	Buy	+7,766	New	+$8.36K	﹤0.01%	5099
2025 Q3	–	Sell	-1,472	Closed	-$1.49K	–	6065
2025 Q2	$1.49K	Buy	+1,472	New	+$1.39K	﹤0.01%	5380
2025 Q1	–	Sell	-12,294	Closed	-$14.4K	–	5545
2024 Q4	$14.4K	Buy	+12,294	New	+$16.3K	﹤0.01%	5318
2022 Q3	–	Hold	0	–	-$43K	–	5789
2022 Q2	–	Hold	0	–	–	–	4597
2022 Q1	–	Hold	0	–	–	–	5108

Other funds holding ALLR

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

MCM

Militia Capital Management Austin, Texas $3.37B AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citigroup's ALLR Position: Q2 2026 in Review

Citigroup sold out of Allarity Therapeutics (ALLR) in Q2 2026, closing a stake of 7,766 shares — an estimated $8.46K sold.

Citigroup first reported a position in ALLR in Q4 2024 and held it in 3 quarters. The position peaked at $14.4K in Q4 2024. 20 funds tracked by Wall St. Rank hold ALLR as of Q2 2026.

Citigroup reported no remaining Allarity Therapeutics position as of Q2 2026 after selling out during the quarter.
Citigroup sold 7,766 Allarity Therapeutics shares in Q2 2026, an estimated $8.46K.
Citigroup first reported a position in Allarity Therapeutics in Q4 2024 and held it in 3 quarters.
Citigroup's Allarity Therapeutics position peaked at $14.4K in Q4 2024.
20 funds tracked by Wall St. Rank held Allarity Therapeutics as of Q2 2026.

Based on Citigroup's 13F filing for Q2 2026, filed 3 Aug 2026.